Veru (VERU) PT Set at $6.00 by Maxim Group

Veru (NASDAQ:VERU) has been assigned a $6.00 target price by investment analysts at Maxim Group in a report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 341.18% from the company’s current price.

Other equities research analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and set a $4.50 price target on shares of Veru in a research note on Wednesday, January 23rd. Zacks Investment Research raised Veru from a “sell” rating to a “buy” rating and set a $1.50 target price for the company in a report on Wednesday, October 17th. Five equities research analysts have rated the stock with a buy rating, Veru has a consensus rating of “Buy” and an average target price of $4.00.

Shares of VERU stock opened at $1.36 on Thursday. Veru has a fifty-two week low of $1.20 and a fifty-two week high of $2.37. The stock has a market cap of $93.47 million, a PE ratio of -3.49 and a beta of 0.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 0.66 and a current ratio of 0.83.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Thursday, December 13th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.05). Veru had a negative return on equity of 56.71% and a negative net margin of 150.89%. The business had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $7.25 million. Sell-side analysts predict that Veru will post -0.23 EPS for the current year.

In related news, insider Mitchell Shuster Steiner sold 25,600 shares of Veru stock in a transaction dated Wednesday, January 23rd. The stock was sold at an average price of $1.34, for a total transaction of $34,304.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Harry Fisch bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 18th. The shares were purchased at an average cost of $1.42 per share, with a total value of $42,600.00. The disclosure for this purchase can be found here. Insiders own 29.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in VERU. Perceptive Advisors LLC acquired a new stake in shares of Veru during the third quarter worth about $2,024,000. AWM Investment Company Inc. lifted its holdings in shares of Veru by 72.4% during the third quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company’s stock worth $1,420,000 after purchasing an additional 420,000 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Veru by 115.4% during the fourth quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock worth $301,000 after purchasing an additional 115,506 shares during the period. BlackRock Inc. lifted its holdings in shares of Veru by 475.1% during the second quarter. BlackRock Inc. now owns 113,563 shares of the company’s stock worth $229,000 after purchasing an additional 93,815 shares during the period. Finally, Hound Partners LLC acquired a new stake in shares of Veru during the third quarter worth about $119,000. 8.54% of the stock is owned by hedge funds and other institutional investors.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Featured Article: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply